Last reviewed · How we verify
Anti-CS17 Bovin IgG — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Anti-CS17 Bovin IgG (Anti-CS17 Bovin IgG) — Johns Hopkins Bloomberg School of Public Health.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-CS17 Bovin IgG TARGET | Anti-CS17 Bovin IgG | Johns Hopkins Bloomberg School of Public Health | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-CS17 Bovin IgG CI watch — RSS
- Anti-CS17 Bovin IgG CI watch — Atom
- Anti-CS17 Bovin IgG CI watch — JSON
- Anti-CS17 Bovin IgG alone — RSS
Cite this brief
Drug Landscape (2026). Anti-CS17 Bovin IgG — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-cs17-bovin-igg. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab